Leap Therapeutics Inc. (LPTX)
NASDAQ: LPTX
· Real-Time Price · USD
0.42
0.03 (6.87%)
At close: Jun 09, 2025, 3:59 PM
Leap Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | 634K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 375K | 375K | 375K | 375K |
Cost of Revenue | n/a | n/a | n/a | n/a | 5K | 110K | 107K | 106K | 104K | 101K | 100K | 106K | 108K | 374.63K | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | -5K | 524K | -107K | -106K | -104K | -101K | -100K | -106K | -108K | 375.00 | 375K | 375K | 375K |
Operating Income | -15.92M | -16.13M | -17.86M | -21.25M | -14.82M | -14.82M | -14.83M | -14.66M | -42.73M | -13.94M | -15.29M | -16.9M | -10.63M | -10.49M | -12.14M | -9.63M | -9.17M |
Interest Income | 437K | 595K | 894K | 865K | 775K | 938K | 1.08M | 1.16M | 848K | 521K | 360K | 39K | 5K | 5K | 1K | 1K | 2K |
Pretax Income | -15.44M | -15.55M | -17.47M | -20.13M | -13.82M | -12.46M | -13.7M | -13.39M | -41.86M | -11.96M | -15.09M | -17.02M | -10.38M | -10.81M | -11.14M | -9.53M | -9.13M |
Net Income | -15.44M | -15.43M | -18.18M | -20.13M | -13.82M | -12.46M | -13.7M | -13.39M | -41M | -12.1M | -15.9M | -17.76M | -10.14M | -10.79M | -11.14M | -9.53M | -9.13M |
Selling & General & Admin | 3.01M | 3.01M | 2.94M | 3.37M | 3.53M | 3.02M | 3.33M | 3.56M | 3.78M | 2.91M | 3.19M | 2.85M | 2.85M | 2.79M | 2.44M | 2.79M | 2.74M |
Research & Development | 12.91M | 13.11M | 14.91M | 17.89M | 11.3M | 11.69M | 11.5M | 11.1M | 38.94M | 11.03M | 12.1M | 14.04M | 7.78M | 8.07M | 10.08M | 7.21M | 6.81M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | 272K | n/a | n/a | -272K | -775K | -652K | -587K | -37K | 1.58M | -1.27M | -244K | -71K |
Operating Expenses | 15.92M | 16.13M | 17.86M | 21.25M | 14.82M | 14.71M | 14.83M | 14.36M | 42.45M | 13.17M | 14.64M | 16.31M | 10.6M | 11.22M | 11.25M | 9.76M | 9.48M |
Interest Expense | -6K | n/a | n/a | n/a | n/a | 863K | n/a | n/a | n/a | 5K | 11K | 17K | 21K | 2K | 9K | 16K | 14K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | -110K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 16.13M | 17.86M | 21.25M | 14.82M | 14.82M | 14.83M | 14.36M | 42.45M | 13.17M | 14.64M | 16.31M | 10.6M | 11.22M | 11.25M | 9.76M | 9.48M |
Income Tax Expense | n/a | -123K | 708K | n/a | -5K | 664K | 199K | -16.09K | -863K | 147K | 807K | 733K | -235K | -24K | 9K | 104K | -88K |
Shares Outstanding (Basic) | 41.27M | 41.25M | 41.21M | 39.12M | 27.01M | 26.99M | 26.99M | 14.71M | 12.93M | 11.32M | 11.32M | 11.32M | 11.32M | 11.31M | 7.82M | 7.64M | 7.64M |
Shares Outstanding (Diluted) | 41.27M | 41.25M | 41.21M | 39.12M | 27.01M | 26.99M | 26.99M | 14.71M | 12.93M | 11.32M | 11.32M | 11.32M | 11.32M | 11.31M | 7.82M | 7.64M | 7.64M |
EPS (Basic) | -0.37 | -0.37 | -0.44 | -0.51 | -0.51 | -0.46 | -0.51 | -0.91 | -3.17 | -1.07 | -1.4 | -1.57 | -0.9 | -0.95 | -1.42 | -1.25 | -1.2 |
EPS (Diluted) | -0.37 | -0.37 | -0.44 | -0.51 | -0.51 | -0.46 | -0.51 | -0.91 | -3.17 | -1.07 | -1.4 | -1.57 | -0.9 | -0.95 | -1.42 | -1.25 | -1.2 |
EBITDA | -15.92M | -16.13M | -18.35M | -21.25M | -14.82M | -12.83M | -13.59M | -13.28M | -41.76M | -11.85M | -14.98M | -16.9M | -10.25M | -10.59M | -11.06M | -9.37M | -9.11M |
EBIT | n/a | -15.55M | -18.35M | -21M | -14.58M | -12.46M | -13.7M | -14.36M | -42.45M | -11.95M | -15.08M | -17.01M | -10.36M | -10.81M | -11.13M | -9.51M | -9.12M |
Depreciation & Amortization | n/a | n/a | -499K | 202K | 5K | 110K | 107K | 106K | 104K | 101K | 100K | 106K | 108K | 217K | 66K | 137K | 136K |